Why This 1 Cannabis Stock Sticks Out Like a Sore Thumb

Looking for growth in a choppy market? Find out now why Green Thumb Industries (CNSX:GTII) isn’t like other cannabis stocks.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It was popular for a while to refer to the cannabis space as another dot-com bubble. There were definitely similarities: a new industry full of potential was getting investors exciting, driving up share prices until the bubble burst. Post-legalization, many of the great green hopes touted by early cannabis bulls were up in smoke, to use a tired idiom. But cannabis still has a market and a tangible commodity.

But does it still have upside? After all, cannabis is a plant that can be grown anywhere and by anyone. In a moment we’re going to take a quick look at a stock that has been garnering some positive press. Its success in 2020 challenges the idea that legal cannabis is drained of momentum.

A pot stock that bucks the trend

Growth investors looking to pump funds into cannabis have a clear winner in Green Thumb Industries (CNSX:GTII). This name just reported Q2 revenue growth of almost 17%. This is pretty remarkable given an exceptionally flat cannabis market oversaturated by too many players. Paying attention to which cannabis names the markets like can pay off for the bold pot stock investor, and this name impresses.

But investors should ask themselves just how sustainable upside might be in a space already dominated by a well-established black market. Beset by a hamstrung retail environment and undermined by the pandemic, the case for cannabis upside has been growing steadily weaker.

Cannabis investors seeking some resilient upside in a frothy broader market may want to stack shares in Green Thumb this summer. This name has seen its share price climb 31% in the past month. Looking back a little further, cannabis investors have pushed this name up more than 50% since mid-June. This is the kind of share price performance that cannabis investors ideally should have seen ever since post-legalization.

Sticking out like a Green Thumb

Investors who have been keeping an eye on cannabis performance are no doubt aware of Green Thumb’s momentum. But the key is to pinpoint whether this is sustainable. A recovery is likely to see cannabis sales bounce back, while an overhauled retail space could also turn its fortunes around.

Green Thumb really sticks out in an industry that has seen one big name disappoint after another. Look at the performance of some of the brightest hopes in the cannabis space. Up 70.3% in 12 months, Green Thumb stock has been more popular than most. Compare that with HEXO’s 82.9% year-on-year decline.

Despite this, future cash flows are projected to be so strong that Green Thumb’s current price is about 80% below fair value. Couple that with the potential for annual earnings growth of around 77% in the next couple of years, and you have the beginnings of a buy thesis.

Green Thumb’s price is relatively attractive at around 3.7 times book. The bottom line for cannabis stock investors, though, has to be that 16.6% sequential Q2 revenue growth. Matched with a potential total one-year return of 72%, this is a highly responsive stock that is impressing investors and generating some strong positive momentum.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »